Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidinesHeinz-Josef Lenz, Eric Van Cutsem, Shirin Khambata-Ford, et al.
Archives of Pathology & Laboratory Medicine|October 4, 2012
Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trialChristopher T Harbison, Christine E Horak, Jean-Marie Ledeine, et al.
The New England Journal of Medicine|October 24, 2008
K-ras mutations and benefit from cetuximab in advanced colorectal cancerChristos S Karapetis, Shirin Khambata-Ford, Derek J Jonker, et al.
Archives of Pathology & Laboratory Medicine|September 2, 2025
QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3-Internal Tandem Duplications for Treatment With QuizartinibJaime E Connolly Rohrbach, Ken C N Chang, Maha Karnoub, et al.
JAMA|October 28, 2010
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximabWendy De Roock, Derek J Jonker, Federica Di Nicolantonio, et al.
Pharmacogenomics|July 27, 2011
Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working groupScott D Patterson, Nadine Cohen, Maha Karnoub, et al.
Virchows Archiv : an International Journal of Pathology|October 19, 2023
Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancerCharo Garrido, Melissa Manoogian, Dhiraj Ghambire, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximabShirin Khambata-Ford, Christopher R Garrett, Neal J Meropol, et al.
Pageof 2